consecutive newly diagnosed stage 4 neuroblastoma patients over 1 year of age were assigned to receive tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) as consolidation therapy. Fifty of the 52 patients underwent a first HDCT/ASCR and 44 patients underwent a second HDCT/ASCR. Eight patients (15.4%) died from treatment-related toxicity (seven during the second HDCT/ ASCR). Total body irradiation (TBI) in the first HDCT/ ASCR and a shorter interval (o12 weeks) between the first and second HDCT/ASCR were associated with a higher rate of treatment-related death in the second HDCT/ASCR (P ¼ 0.032 and 0.095, respectively). The tumor relapsed or progressed in 11 patients, and 33 patients remained event free with a median follow-up of 53 months (range 19-117) from diagnosis. The 5-year eventfree survival (EFS) (795% confidence interval) for all 52 patients was 62.1713.7%. The application of TBI and local radiotherapy, and a longer interval between the first and second HDCT/ASCR were independently associated with a better EFS (P ¼ 0.026, 0.007 and 0.020, respectively). However, further studies will be needed to decrease the toxic death rate in the second HDCT/ASCR while reducing the relapse rate.
Introduction
The prognosis of high-risk neuroblastoma after conventional chemoradiotherapy is generally poor. [1] [2] [3] Therefore, a strategy using high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) has been explored to improve the prognosis of patients with high-risk neuroblastoma. [2] [3] [4] [5] This strategy is based on the hypothesis that dose escalation might improve the survival of children with high-risk neuroblastoma. The results of randomized trials comparing HDCT/ASCR with chemotherapy alone showed a better event-free survival (EFS) in the HDCT/ ASCR arm than in the continuous chemotherapy arm. 3, 6 However, the overall EFS was unsatisfactory.
In this context, some studies have examined the efficacy of double or triple tandem HDCT/ASCR to improve further the outcome of high-risk neuroblastoma patients. [7] [8] [9] Grupp et al. carried out a single arm trial of tandem transplantation as consolidation therapy and reported improved long-term survival (5-year progression-free survival 47%) with acceptable toxicity. 8 Kletzel et al. 9 also conducted a single-arm trial of triple-tandem transplantation and reported improved survival (3-year EFS 57%). These demonstrated that further dose escalation might result in further improvements in the EFS of high-risk neuroblastoma patients.
This study examined the efficacy of tandem HDCT/ ASCR to determine if further dose intensification might improve the EFS in patients over 1 year of age with stage 4 neuroblastoma.
Patients and methods

Patients
From June 1997 to August 2005, 52 consecutive newly diagnosed stage 4 neuroblastoma patients over 1 year of age at diagnosis at the Samsung Medical Center were assigned to receive tandem HDCT/ASCR as consolidation therapy after induction therapy. A diagnosis of neuroblastoma was made based on either histological examination of the tumor specimens or bone marrow infiltrated with neuroblastoma cells and elevated urine catecholamine levels. The MYCN copy number was determined using Southern blot analysis or quantitative reverse transcriptase (RT-PCR). The patients were staged according to the criteria reported by Brodeur et al. 10 and the extent of the disease was evaluated using computerized tomography, a technetium-99 ( 99 Tc) bone scan, bilateral bone marrow aspirates and biopsy specimens, and an iodine-131 or 123-metaiodobenzylguanidine scan. Samsung Medical Center Institutional Review Board approved the protocols used for HDCT/ASCR, and written informed consent was obtained from the parents of each patient. Figure 1 gives a summary of the treatment plan. Each induction chemotherapy cycle was scheduled to be 28 days apart, but some delays were permitted to allow the absolute neutrophil count (ANC) and platelet count to recover to 1.0 Â 10 9 and 100 Â 10 9 /l, respectively. The patients received 5-10 mg/kg of s.c. human granulocyte-colony stimulating factor (G-CSF) daily if the ANC fell below 0.5 Â 10 9 /l after chemotherapy.
Induction therapy
In the early period of this study (diagnosis by December 2003), we planned to perform definitive surgery after five cycles of induction chemotherapy except for those patients who had undergone a surgical resection of their primary tumor before the administration of induction chemotherapy. If it was difficult to debulk the tumor after five cycles of chemotherapy, an additional 1-2 cycles of chemotherapy were given before the definitive surgery. The CEDC regimen was used as the primary chemotherapy (Table 1) . If there was no evidence of tumor in the bone marrow after surgery, the peripheral blood stem cells (PBSCs) were collected during the next chemotherapy cycle after surgery. If there was any evidence of tumor in the bone marrow, the conventional chemotherapy regimen was usually changed to an ICE regimen (Table 1) , and PBSC collection was deferred until no tumor cells were detected in the bone marrow. After collecting the PBSCs, 0-2 additional cycles of chemotherapy were given for scheduling HDCT/ASCR.
In the late period of this study (diagnosis from January 2004), six cycles of chemotherapy were given before definitive surgery except for those patients who had undergone a surgical resection before the administration of induction chemotherapy. The CEDC and ICE regimens were used in an alternating manner. The PBSCs were collected during the seventh chemotherapy cycle if the bone marrow was clear. If there was any evidence of tumor in the bone marrow at the seventh cycle of chemotherapy, PBSC collection was deferred until no tumor cells were detected. Overall, 9-10 cycles of chemotherapy were administered.
PBSC collection
The patients received 5-10 mg/kg of s.c. G-CSF daily if the ANC fell below 0.5 Â 10 9 /l after chemotherapy, and G-CSF was continued until the completion of leukapheresis. Leukapheresis was started when the white blood cell count exceeded 1.0 Â 10 9 /l with a monocytosis after nadir. The aim was to collect minimum 2 Â 10 6 CD34 þ cells/kg (hopefully 45 Â 10 6 ) to rescue the tandem HDCT with the PBSCs collected during a single leukapheresis round. Another leukapheresis round was carried out when the number of CD34 þ cells collected was insufficient.
Tandem HDCT and ASCR After the completion of induction therapy, the patients underwent tandem HDCT/ASCR. Table 2 lists the HDCT regimens used in this study. Briefly, the principal regimens employed for the first HDCT were CEM-total body irradiation (TBI) in the early period and CEC in the late period. The principal regimens for the second HDCT were CTM or BM in the early period and TM-TBI in the late period. While TBI was included in the first HDCT during the early period of this study, it was administered in the second HDCT during the late period because it was suspected that TBI in the first HDCT/ASCR might have been one of the causes for the high toxic death rate in the second HDCT/ASCR during the early period of this study. The second HDCT/ASCR was given only if the platelet count exceeded 50 Â 10 9 /l after the first HDCT/ASCR without a transfusion and there was no evidence of a significant organ dysfunction. Approximately half of the collected PBSCs were infused for marrow rescue at each HDCT session. Three to five cycles of conventional chemotherapy were administered to the six patients who did not show a complete response (CR) after the first HDCT/ASCR to reduce the tumor burden before the second HDCT/ASCR according to the decision of the physicians.
Local radiotherapy
In the early period of this study, local radiotherapy (15-30.6 Gy/1.5-1.8 Gy) was given to the primary site only if the gross residual tumor remained after surgery. However, in the late period of this study, local radiotherapy (15/1.5 Gy in the case of complete resection of the primary tumor and 21.6/1.8 Gy in the case of incomplete resection) was administered to all patients 6 weeks after the second HDCT/ASCR (Figure 1 ).
Post-HDCT treatment
Thirteen-cis-retinoic acid (CRA) was usually used for 10 cycles (125 mg/m In the early period
In the late period
Tandem HDCT and ASCR in high-risk neuroblastoma patients KW Sung et al for 2 weeks). 11 IL-2 immunotherapy was usually initiated when the platelet count exceeded 50 Â 10 9 /l without a transfusion after the second HDCT/ASCR. The first dose of IL-2 was begun on the first day of the CRA treatment cycle and was applied until 1 year after the second HDCT/ ASCR. These two drugs were used simultaneously because their major toxicities do not overlap, and their different mechanisms of action might synergize in eradicating the minimal residual disease.
Response criteria
The international response criteria were used to evaluate the treatment response. 10 Briefly, CR was defined as no identifiable tumor with normal catecholamine. A very good partial response (VGPR) was defined as a decrease in the primary tumor by 90-99% with normal catecholamine with or without any residual 99 Tc bone changes. A partial response (PR) was defined as a reduction of the primary tumor and metastatic tumor by more than 50%. The toxicity was recorded according to the common toxicity criteria of the National Cancer Institute of USA.
Detection of neuroblastoma cells by quantitative RT-PCR for tyrosine hydroxylase mRNA
During the late period of this study, the PBSCs collected were tested for the presence of tumor cell contamination using quantitative RT-PCR for tyrosine hydroxylase mRNA, as described elsewhere.
12,13
Statistics
The survival rate along with 95% confidence interval (CI) was estimated using the Kaplan-Meier method. An event was defined as the occurrence of a relapse, progression or treatment-related death. The differences in the survival rates between the two groups were compared using the logrank test. The differences in the frequencies of venoocclusive disease (VOD) and the treatment-related toxic death between the two groups were analyzed using the Fisher's exact test. The differences in the ANC and platelet recovery between the first and second HDCT/ASCR were analyzed using a paired t-test. Multivariate analyses comprising the prognostic factors with a P-value o0.1 determined by univariate analysis for the EFS were performed using Cox regression analysis. P-values o0.05 were considered significant. Table 3 lists the clinical and biological characteristics of the 52 patients. The median age at diagnosis was 36 months (range 13-129), and 40 patients were over 24 months of age at diagnosis. Twenty-nine out of 50 tumors analyzed were MYCN-amplified, and 20 patients had multiorgan (X3) metastases. A gross total resection (GTR) was achieved in 19 out of 48 patients. A surgical resection could not be performed in four patients because of an unknown primary tumor (n ¼ 2), an excellent response to induction treatment (too small to remove, n ¼ 1) and tumor progression before surgery (n ¼ 1). Overall, a median of eight cycles (range 6-12) of chemotherapy was administered before the first HDCT/ASCR. Twenty-four patients received X9 cycles of induction chemotherapy before the first HDCT/ASCR and 35 patients received local radiotherapy. There were no toxic deaths during the induction therapy.
Results
Patients characteristics and induction treatment
Feasibility of PBSC collection
The PBSCs were collected during the 6th to 8th chemotherapy cycle in 42 patients. PBSC collection was deferred in eight patients because of persistent tumor cells in the bone marrow after surgery. In two patients, a differentiated tumor cell clump was present in the bone marrow despite the additional cycles of chemotherapy, and the stem cells were collected with persistent tumor cells in the bone marrow. A median of 4.6 Â 10 6 CD34 þ cells/kg (range 1.4-24.9) were collected during the first leukapheresis round with a median of 6.5 leukapheresis events (range 2-11). Nine patients underwent a second leukapheresis round to collect a sufficient number of PBSCs. Generally, the leukapheresis procedure was well tolerated and no patient developed significant toxicity except for thrombocytopenia requiring a transfusion after leukapheresis. During the late period of this study, quantitative RT-PCR for tyrosine hydroxylase mRNA was performed to detect possible tumor cell contamination in the PBSCs collected from 18 patients, and no mRNA transcript was detected. Figure 2 shows the flow of the patients from diagnosis through tandem HDCT/ASCR. Fifty out of 52 patients underwent at least one HDCT/ASCR. The tumor progressed in two patients before the first HDCT/ASCR. The tumor status before the first HDCT was 14 in CR, 30 in VGPR and six in PR. The median age at the first HDCT/ ASCR was 45.5 months (range 24-140). Tumor status after the first HDCT/ASCR was 21 in CR, 21 in VGPR and six in PR, one in progression and one who could not be evaluated because of toxic death. Six out of 50 patients could not proceed to the second HDCT/ASCR because of tumor progression after the first HDCT/ASCR in one, toxic death during the first HDCT/ASCR in one, and the request by the parents of four who were in fear of toxic death during the second HDCT/ASCR. All of these four patients were in CR after the first HDCT/ASCR and three of them have been free of disease for 62, 63 and 117 months since the diagnosis. Overall, 44 patients underwent the second HDCT/ASCR. The median time from the first infusion of PBSCs to the initiation of the second HDCT was 82.5 days (range 43-323). In six patients, the interval between the first and second HDCT/ASCR was more than 200 days because conventional chemotherapy had been administered before the second HDCT/ASCR. In five patients, TBI was not administered at the request of the parents, who were in fear of the short-term and long-term toxicity of TBI. /l was 11 days (range 10-25) and 44.5 days (range 15-543), respectively. When the analysis was confined to only those patients who had received tandem transplantation, the platelet recovery was significantly delayed in the second transplantation compared with the first (median 23.5 days versus 44.5 days, P ¼ 0.007).
Tandem HDCT/ASCR
Hematological recovery
Toxicity of tandem HDCT/ASCR
The median duration of high fever (body temperature X38.51C) during the first and second HDCT/ASCR were 2 and 1 days, respectively. There were seven positive blood cultures (four in the first and three in the second HDCT/ ASCR). The grade X3 toxicities that frequently developed in more than 1/3 of patients were stomatitis, vomiting, diarrhea, an elevation of the liver enzyme and hypokalemia. The frequency of VOD was higher in the second HDCT/ ASCR (eight out of 44) than in the first HDCT/ASCR (three out of 50) (P ¼ 0.065). A total of eight toxic deaths (15.4%) were encountered during the tandem cycles of HDCT/ASCR, which were attributed to VOD in three, viral pneumonia in two, pulmonary hemorrhage in one, sepsis in one and congestive heart failure in one. The toxic death rate was significantly higher during the second HDCT/ASCR (seven out of 44) than in the first HDCT/ ASCR (one out of 50) (P ¼ 0.019). TBI in the first HDCT and a shorter interval (o12 weeks) between the first and second HDCT/ASCR were associated with a higher incidence of toxic death in the second HDCT/ASCR (P ¼ 0.032 and 0.095, respectively). All seven toxic deaths in the second HDCT/ASCR occurred in those patients who had received TBI in the first HDCT/ASCR. However, a longer treatment duration (X9 cycles of chemotherapy) before the first HDCT/ASCR was not significantly associated with a higher rate of toxic death during the 
Feasibility of post-HDCT/ASCR therapy
Skin eruption, particularly on the face, was a common side effect of the CRA treatment. High fever, thrombocytopenia and local inflammation were frequent side effects of IL-2 therapy. However, all the patients tolerated the differentiation therapy and immunotherapy well and there was no grade X3 toxicity that required the discontinuation of treatment during the post-HDCT/ASCR therapy.
Survival of patients
The tumor relapsed or progressed in 11 patients (seven after the second HDCT/ASCR) and 33 out of 52 patients remained event-free with a median follow-up of 53 months (range 19-117) from diagnosis. The 5-year OS and EFS rate (795% CI) for all 52 patients was 64.3714.3% and 62.1713.7%, respectively. Figure 3a shows the results of Kaplan-Meier analysis for EFS of the 52 patients. Univariate analysis showed that the EFS rate of those patients with X3 organ metastases was significantly worse than in patients with 1-2 organ metastases. Tumors originating from the abdomen had a worse prognosis than those originating from other sites with borderline significance. The application of TBI, the application of local RT and a longer interval (X12 weeks) between the first and second HDCT/ASCR were associated with a better EFS ( Table 3 ). The EFS in those patients treated for longer periods (X9 cycles of chemotherapy) before HDCT/ASCR was also higher than in patients treated for shorter periods (p8 cycles) (78.3716.9 versus 53.9719.2%, P ¼ 0.058). This difference was more prominent when the analysis was confined to only those patients with very high-risk features such as MYCN amplification (90.9717.0 versus 37.5723.7%, P ¼ 0.012) or multi-organ (X3 organ) metastases (68.6729.7 versus 25.0730.0%, P ¼ 0.052).
Multivariate analysis for the EFS (Table 4 ) revealed the application of TBI, the application of local radiotherapy, a longer interval (X12 weeks) between the first and second HDCT/ASCR, and the tumor originating from extraabdominal sites to be independent favorable predictors for EFS (P ¼ 0.026, 0.007, 0.020 and 0.035, respectively). In addition, a longer treatment duration (X9 cycles of chemotherapy) before HDCT/ASCR was an independent favorable predictor with borderline statistical significance (P ¼ 0.069). When the analysis was confined to only those who had received both TBI and local radiotherapy (n ¼ 30), the 5-year EFS rate after the first HDCT/ASCR was 89.7711.0% (Figure 3b ).
Discussion
Although the strategy using HDCT/ASCR has improved the survival of patients with high-risk neuroblastoma, the survival rate after single HDCT/ASCR has been unsatisfactory. [2] [3] [4] [5] Therefore, this study examined the efficacy of tandem HDCT/ASCR to improve further the treatment outcome of high-risk neuroblastoma patients. This study was based on the hypothesis that further dose escalation might result in further improvements in the EFS of highrisk neuroblastoma patients. The results showed a better long-term EFS compared with those reported in other studies using a single HDCT/ASCR strategy. The survival rate in this study appeared to be similar to or slightly better than those reported in studies that used a tandem double or tandem triple HDCT/ASCR strategy. 8, 9 According to several studies evaluating the presence of minimal residual disease at the time of PBSC harvest in advanced neuroblastoma, tumor cell contamination was detected in many patients by either immunocytologic analysis or RT-PCR for tyrosine hydroxylase mRNA. Tumor cell contamination might be one reason for the relapse after HDCT/ASCR. 18 In this study, PBSC collection was deferred until no tumor cells were detected in the bone marrow to avoid possible tumor cell contamination in the PBSCs, and the timing of PBSC collection was delayed compared with other studies. 8, 9 Therefore, relatively fewer CD34 þ cells were collected and infused to rescue the first and second HDCT. However, there was no evidence of tumor cell contamination in the collected PBSCs and the hematological recovery was clinically acceptable even though platelet recovery in the second HDCT/ASCR was delayed compared with the first HDCT/ASCR. The infusion of PBSCs free of tumor cells might have contributed to the lower relapse rate in this study.
Overall, eight toxic deaths (15.4%) occurred during the tandem cycles of HDCT/ASCR. A relatively more intense regimen compared with those used in other studies using a sequential HDCT/ASCR strategy might have caused the higher toxic death rate in this study. While the toxic death rate in the first HDCT/ASCR (2%) was acceptable, that in the second HDCT (15.9%) was high. Similarly, VOD developed more frequently in the second HDCT/ASCR compared with the first HDCT/ASCR. TBI in the first HDCT/ASCR was significantly associated with a higher toxic death rate in the second HDCT. In the late period of this study, there was no toxic death during the second HDCT/ASCR when TBI was given at the second HDCT/ ASCR. A shorter interval between the first and second HDCT/ASCR was also associated with a higher toxic death rate in the second HDCT/ASCR. This suggests that sufficient rest after the first HDCT/ASCR is needed when both first and second HDCT are intensive, as in our tandem HDCT regimen.
TBI was administered as a part of the HDCT/ASCR in 45 out of 50 patients who had received at least single HDCT/ASCR. The EFS in the patients who had received TBI was better than in those patients who did not receive TBI. Although there is some controversy regarding the efficacy of TBI, we believe that a regimen with TBI is better than a regimen without in terms of the survival of patients with a high-risk neuroblastoma. Moreover, we recommend that TBI should be included in the second HDCT/ASCR if TBI is included in a tandem HDCT regimen because TBI in the first HDCT was found to be associated with a higher toxic death rate in the second HDCT.
The outcome of patients who received local radiotherapy was better than those who did not. Multivariate analysis revealed the application of local radiotherapy to be a strong independent favorable factor for the EFS. No randomized trials have been performed to determine if local radiotherapy is an effective modality in the treatment of highrisk patients. However, these results suggest that local radiotherapy might be effective in eradicating the tumor in high-risk patients. During the early period of this study, local radiotherapy was not given if GTR was possible. This might explain the poorer outcome of those patients in whom GTR was possible compared with those in whom GTR was not possible and local radiotherapy was given.
Intensive myeloablative chemotherapy and radiation therapy (particularly TBI) may improve the survival of patients with high-risk neuroblastoma, but may also increase the frequency and severity of long-term side effects such as a secondary malignancy in the future. 19, 20 No secondary malignancy developed in this study. However, a longer follow-up will be needed.
The duration of induction therapy proved to be an important prognostic factor for long-term EFS in this study. Kushner et al. 22 recently reported that five cycles of induction regimen resulted in similar antitumor response to that after seven cycles of induction regimen in the interim analysis, and they could not observe any antitumor benefit from cycles 6 and 7. In addition, they reported that there was more toxicity in the seven cycles of induction regimen and prolonged thrombocytopenia after cycles 6 and 7, which sometimes caused delays in starting consolidative therapy. They concluded that seven cycles of induction chemotherapy might adversely affect the long-term outcome. However, they did not demonstrate a difference in the long-term outcome after HDCT/ASCR between the two groups. In this study, there was also no difference in the tumor status after induction therapy between the longer (20 out of 24 patients in CR/VGPR) or shorter (24 out of 26 patients in CR/VGPR) induction treatment. However, the patients treated for longer periods had a better long-term EFS than those patients treated for shorter periods. This difference was more prominent when the analysis was confined only to those patients with very high-risk features such as MYCN amplification or multi-organ metastases. A longer treatment duration was associated with a lower relapse rate after HDCT/ASCR, but was not associated with a higher toxic death rate during tandem HDCT/ASCR. The relatively longer induction treatment compared with other studies might have contributed to the improved survival in this study. Similar results were found in two European studies. 4, 21 According to the reports from the European Bone Marrow Transplantation Solid Tumor Registry, a longer treatment duration (412 months) was also associated with a better outcome that could not be explained by other prognostic factor. They suggested that the transferal to major transplant centers predisposes the cohort to a better outcome due to preselection. 4 However, in this study, all the patients had a newly diagnosed tumor. Furthermore, a longer induction treatment (X9 courses of chemotherapy) was also significantly associated with a better outcome even among patients who had been transferred to our hospital for transplant during the same period in this study (5-year EFS 100 versus 12.5%, P ¼ 0.001). This suggests that a longer induction treatment before HDCT/ASCR is associated with a better outcome regardless of the transferral and suggests that sufficient tumor control before HDCT/ASCR is very important for achieving a successful long-term outcome. We believe that a longer induction treatment is associated with a lower tumor burden at HDCT/ASCR even though there was no difference in the tumor status between longer and shorter induction treatment in this study according to the conventional criteria. These findings suggest that the criteria for the treatment response proposed by Brodeur et al. 10 may have limited value in predicting the outcome after HDCT/ ASCR. According to the report from the European Bone Marrow Transplantation Solid Tumor Registry, the tumor status before HDCT/ASCR was not associated with the outcome after HDCT/ASCR.
Immunotherapy with IL-2 along with CRA was applied in an attempt to control the minimal residual disease after HDCT/ASCR. While the efficacy of CRA has been demonstrated, there have been few studies that have evaluated the efficacy of IL-2 therapy. Therefore, it is unclear if IL-2 therapy contributed to the improved survival in this study. However, there was no lifethreatening toxicity and an increase in the number of natural killer cells was observed after IL-2 therapy. More study will be needed to evaluate the efficacy of the IL-2 treatment after HDCT/ASCR.
The analysis in this study was performed in a prospective manner because all the patients were assigned to receive tandem HDCT/ASCR at diagnosis. However, throughout this study, multiple modifications were made in the treatment plan, which resulted in significant variability over time between patients. This variability may create doubt as to whether tandem HDCT/ASCR itself resulted in the improved outcome. For example, a longer induction treatment compared with other studies might have had an impact on the EFS in this study. Ironically, this variability in the treatment helped identify the factors important for improving the outcome of tandem HDCT/ASCR. Further study will be needed to reduce the toxic death rate in the second HDCT/ASCR while maintaining or reducing the relapse rate after intensive tandem HDCT/ASCR.
